Navigation Links
Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
Date:11/3/2008

EMERYVILLE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced it has received a quarterly royalty payment of approximately $2.0 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of moderate-to-severe Alzheimer's disease. Under an exclusive marketing agreement, NTI currently receives quarterly royalty payments on certain sales of Memantine by Merz and its marketing partners.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
3. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
4. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. Neurobiological Technologies Sets Date for Second Quarter Financial Results
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  The global market for ... according to a new report from Kalorama Information.  ... is performed to evaluate disease progression, monitor drug ... other reasons.  The healthcare market research firm,s report, ... provides an overview of the medical laboratory industry ...
(Date:3/27/2017)... , March 27, 2017  Trovagene, Inc. (NASDAQ: ... its Chief Executive Officer, Bill Welch , will ... 4, 2017 at 9:00 AM EDT at the Essex ...  Bill Welch, and Chief Scientific Officer, Mark Erlander ... investors during the conference.   The presentation will ...
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has ... Research - Global Strategic Business Report" report to their offering. ... This report ... in US$ Million. Annual estimates and forecasts are provided for the ... primary and secondary research. The report profiles 25 ...
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, Jake Lubinski, describes ... characteristics when deformed, which is identical to how the human discs work to ... and return to its natural state along a hysteresis curve, exactly like a ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Vigilant ... company serving law enforcement agencies, announced today the appointment ... as director of public safety business development. ... law enforcement experience, including a focus on the aviation ... his most recent position, Mr. Sheridan served as the ...
(Date:3/9/2017)... , Australia , March 9, ... study data at the prestigious World Lung Imaging Workshop ... Andreas Fouras , was invited to deliver the ... pulmonary medicine. This globally recognised event brings together leaders ... share the latest developments in lung imaging. ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
Breaking Biology News(10 mins):